Concert Pharma tries for a $75M note in IPO

Concert Pharmaceuticals will see if investors are ready to buy in to the biotech's approach to improving therapies with its deuterium-tweaking technology. The Lexington, MA-based biotech has filed for a $75 million IPO. Under CEO Roger Tung, Concert has struck a series of collaborations, including a $300 million deal with Celgene ($CELG) to improve its cancer and anti-inflammatory drugs. Concert's business plan has relied on partnerships to help fund the company as it pursues a mid-stage program for its own in-house program, CTP-499 for diabetic kidney disease. And it's banking on a simple scientific concept: proposing to stabilize drugs with deuterium in such a way as to redefine compounds, making them less threatening on the side-effect front and more promising in terms of efficacy. Concert plans to list as $CNCE. S-1

Suggested Articles

Biogen stunned the biotech world Tuesday when it said it would file aducanumab for approval. Now that the dust has settled, what are analysts saying?

Biocytogen uses chromosome engineering for the in situ replacement of mouse antibody genes with the human counterparts.

Eli Lilly is canning the lead program for the crown jewel of its $1.6 billion Armo buyout after the drug put up a poor showing in pancreatic cancer.